- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00310115
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy
Smoking Relapse Prevention Among Postpartum Women
RATIONALE: Motivational counseling may help prevent pregnant women from smoking again after pregnancy.
PURPOSE: This randomized clinical trial is studying three different types of counseling to see how well they work in preventing smoking relapse after pregnancy in pregnant women who quit smoking during pregnancy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Develop and evaluate 2 "Motivational Relapse Prevention" (MRP) treatments of varying intensity for reducing postpartum smoking relapse among pregnant women who quit smoking during pregnancy.
- Assess MRP and Enhanced MRP (MRP+) effects on treatment mechanisms and the role of those mechanisms in mediating MRP and MRP+ effects on abstinence.
- Assess the cost-effectiveness of both the MRP and MRP+ treatments relative to each other and to usual care for reducing postpartum smoking relapse.
OUTLINE: This is a randomized study. Participants are randomized to 1 of 3 intervention arms.
- Arm I (usual care [UC]): Participants receive self-help materials and brief relapse prevention advice based on the Treating Tobacco Use and Dependence Clinical Practice Guideline.
- Arm II (motivational relapse prevention [MRP]): Participants receive the same intervention as in arm I. Participants also undergo telephone counseling over 30 minutes at 34 and 36 weeks gestation and then at 2, 4, 7, and 16 weeks postpartum.
- Arm III (enhanced MRP [MRP+]): Participants receive the same intervention as in arm I and telephone counseling as in arm II. Participants also undergo in-person counseling over 1 hour at 30-33 weeks gestation and then at 8 weeks postpartum.
Participants in all arms complete questionnaires at baseline, at 30-33 weeks gestation, and then at 8 and 26 weeks postpartum.
Participants are followed at 8 and 26 weeks postpartum.
PROJECTED ACCRUAL: A total of 450 participants will be accrued for this study.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030-4009
- University of Texas MD Anderson Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- age 18 or older
- former smoker who quit during pregnancy as assessed via self-report
- smoked an average of greater than or equal to 1 cigarette per day during the year prior to the current pregnancy
- gestational age < 33 weeks and ability to attend an in-person visit at University of Texas MD Anderson Cancer Center (UTMDACC) between 30-33 weeks of gestational age
- can speak, read and write in English.
- must have a functioning home or personal cell phone
Exclusion Criteria:
1) high-risk pregnancy or known negative birth outcome
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Smoking Prevention Usual Care
Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
|
Usual care of self-help materials and advice for staying cigarette free
|
MRP
Arm II (motivational relapse prevention [MRP]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 & 36 weeks gestation then at 2, 4, 7, & 16 weeks postpartum.
|
Usual care of self-help materials and advice for staying cigarette free
6 x 30 minute counseling sessions over the telephone
2 in-person counseling sessions
|
Enhanced MRP +
Arm III (enhanced MRP [MRP+]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation & 8 weeks postpartum.
|
Usual care of self-help materials and advice for staying cigarette free
6 x 30 minute counseling sessions over the telephone
2 in-person counseling sessions
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Patients with Smoking Abstinence
Tidsram: 26 weeks
|
Smoking abstinence as measured by the Society for Research on Nicotine and Tobacco Smoking Status Measure at 26 weeks following study treatment
|
26 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Cigarettes Smoked Daily
Tidsram: 26 weeks following study treatment
|
Cigarettes smoked per day at 26 weeks following study treatment
|
26 weeks following study treatment
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: David Wetter, PhD, BS, BA, M.D. Anderson Cancer Center
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- icke-småcellig lungcancer
- matstrupscancer
- Blåscancer
- magcancer
- bukspottskörtelcancer
- njurcellscancer
- småcellig lungcancer
- livmoderhalscancer
- orofaryngeal cancer
- larynxcancer
- hypofarynxcancer
- primär levercancer hos vuxna
- cancer i läppar och munhålor
- nasofaryngeal cancer
- paranasal sinus och cancer i näshålan
- akut myeloid leukemi hos vuxna
- tobaksmissbruk
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Kemiskt inducerade störningar
- Matsmältningssystemets sjukdomar
- Substansrelaterade störningar
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Urologiska neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Urologiska sjukdomar
- Sjukdomar i urinblåsan
- Uterina neoplasmer
- Genitala neoplasmer, hona
- Livmoderhalssjukdomar
- Livmodersjukdomar
- Sjukdomar i det endokrina systemet
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Magsjukdomar
- Neoplasmer i endokrina körtel
- Leversjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Neoplasmer i huvud och hals
- Esofagussjukdomar
- Bukspottkörtelsjukdomar
- Uterina cervikala neoplasmer
- Neoplasmer i magen
- Lungneoplasmer
- Störning av tobaksbruk
- Neoplasmer i urinblåsan
- Pankreatiska neoplasmer
- Neoplasmer i levern
- Esofagusneoplasmer
Andra studie-ID-nummer
- BS01-178
- P30CA016672 (U.S.S. NIH-anslag/kontrakt)
- R01CA089350 (U.S.S. NIH-anslag/kontrakt)
- MDA-BS01-178 (Annan identifierare: UT MD Anderson Cancer Center)
- CDR0000466327 (Registeridentifierare: NCI PDQ)
- NCI-2010-01136 (Registeridentifierare: NCI CTRP)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Njurcancer
-
Fayoum UniversityCairo UniversityHar inte rekryterat ännuSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Medical University of ViennaAvslutadSekundär hyperparatyreos | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NjurersättningÖsterrike
-
Hans BahlmannLinkoeping UniversityRekryteringNjurcancer | Uretercancer | Andra specificerade störningar av njure och urinledare | Benign Neoplasm av Ureter | Calculus of Kidney and Ureter | Ureterisk reflux | Medfödd ureteranomali | Benign renal neoplasmSverige
Kliniska prövningar på Smoking Prevention Usual Care
-
Women and Infants Hospital of Rhode IslandNational Institute of Mental Health (NIMH)AvslutadDepression | Depression, postpartumFörenta staterna